Lucid Diagnostics Inc. (LUCD) vs MaxCyte, Inc. (MXCT)
A side-by-side comparison of Lucid Diagnostics Inc. and MaxCyte, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
LUCD
Lucid Diagnostics Inc.
$0.60HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
MXCT
MaxCyte, Inc.
$1.09HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — LUCD vs MXCT
growth of $100 · dividends reinvested · last 5yLUCD -95.0% (-45.0%/yr)MXCT -90.0% (-37.0%/yr)MXCT compounded faster over this window
LUCD MXCT
LUCD vs MXCT: by the numbers
- •MXCT is the larger company ($117M vs $114M market cap).
- •Both run net losses; MXCT's is the smaller (-114.77% vs -959.76% net margin).
Metrics side by side
Valuation
| Metric | LUCD | MXCT |
|---|---|---|
| P/S ratio | 21.02 | 3.76 |
| P/B ratio | 10.48 | 0.74 |
Profitability
| Metric | LUCD | MXCT |
|---|---|---|
| Gross margin | -60.26% | 79.43% |
| Operating margin | -1054.82% | -137.12% |
| Net margin | -959.76% | -114.77% |
| ROE | -478.26% | -22.45% |
| ROIC | -145.10% | -19.83% |
Growth (annualized)
| Metric | LUCD | MXCT |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 1.46% |
| Total return CAGR (5Y) | N/A | -37.32% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.